Cellens Is Collaborating With Bruker BioAFM, A Business Unit Of Bruker, To Develop The World's First Clinical Diagnostic Tests That Leverage Multi-parametric, Single-cell Biophysical Markers And Machine Learning

6/25/24 7:06:39 AM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $BRKR alert in real time by email

Based on cellular biophysical markers attained using Bruker's advanced atomic force microscopy, Cellens is developing its platform for detecting bladder cancer using voided urine samples from cancer patients. The technology has shown outstanding sensitivity and specificity in pilot clinical studies.

Get the next $BRKR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BRKR

Date	Price Target	Rating	Analyst
10/15/2024	$75.00	Overweight	Barclays
9/30/2024		Outperform → Peer Perform	Wolfe Research
8/28/2024	$78.00	Overweight	Wells Fargo
6/3/2024	$85.00	Buy	Jefferies
2/14/2024	$60.00 → $90.00	Neutral → Overweight	JP Morgan
12/19/2023	$72.00	Equal Weight	Wells Fargo
12/13/2023	$80.00	Outperform	Wolfe Research
10/21/2022	$70.00	Buy	UBS

More analyst ratings

$BRKR
Press Releases

Fastest customizable press release news feed in the world

Bruker Announces Quarterly Dividend
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and
11/18/24 7:00:00 AM ET
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials
Bruker Corporation to Present at Upcoming Investor Conferences
Bruker Corporation (NASDAQ:BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Stifel 2024 Healthcare Conference in New York City Monday, November 18, 2024, at 8:35 a.m. Eastern Time Wolfe Research 2024 Healthcare Conference in New York City Tuesday, November 19, 2024, at 4:10 p.m. Eastern Time Nasdaq 51st Investor Conference in London, UK Tuesday, December 10, 2024, at 6:30 a.m. Eastern Time Live audiovisual webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. Replays of the presentations will be posted in
11/12/24 7:00:00 AM ET
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials
Dragonfly Energy and Bruker Partner to Accelerate Battery Technology Development
This strategic partnership leverages the complementary strengths of Dragonfly Energy and Bruker, bringing Dragonfly Energy's thorough expertise in liquid and solid-state battery technology together with Bruker's comprehensive suite of analytical solutions for battery research, development and manufacturingThe collaboration provides a path toward improving Dragonfly Energy's current and next-generation battery technologies and analytical testing methods using Bruker equipment and analytical expert knowledgeBruker's involvement greatly enhances Dragonfly Energy's in-depth scientific understanding of batteries and battery materials through advanced analytical methods based on magnetic resonance
11/12/24 7:00:00 AM ET
$BRKR
$DFLI
Biotechnology: Laboratory Analytical Instruments
Industrials
Industrial Machinery/Components
Miscellaneous

$BRKR
Leadership Updates

Live Leadership Updates

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic
4/4/24 8:11:00 AM ET
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials
Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup
ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral disease ELITechGroup has its R&D, manufacturing and commercial focus on Europe and the Americas Bruker to acquire ELITechGroup revenues of ~Euro 150 million p.a. with >80% consumables revenue Bruker Corporation (NASDAQ:BRKR) announced today that
2/28/24 7:00:00 AM ET
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials
Bruker Announces Agreement to Acquire Chemspeed
Chemspeed Accelerates Bruker's Laboratory Automation and Digitalization Drive Bruker Corporation (NASDAQ:BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240125759758/en/Chemspeed's modular, compact FLEX automation workstations enhance chemical and materials science R&D and lab
1/25/24 7:00:00 AM ET
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials

Bruker Announces Quarterly Dividend
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and
11/18/24 7:00:00 AM ET
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials
Bruker Announces Date and Time of Third Quarter 2024 Earnings Release and Webcast
Bruker Corporation (NASDAQ:BRKR) today announced it will report third quarter 2024 financial results before market opening on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q3 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-
10/28/24 4:05:00 PM ET
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials
Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery
Combining Dynamic Biosensors' Innovative Technologies with Bruker's High-Performance SPR Portfolio to Establish a Leading Biosensors Business Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker's biophysical portfolio for the analysis of molecular interactions and kinetics, offering deeper insights into both inter-molecular and molecule-single cell interactions in drug discovery or basic research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202
10/2/24 7:00:00 AM ET
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials

Cellens Is Collaborating With Bruker BioAFM, A Business Unit Of Bruker, To Develop The World's First Clinical Diagnostic Tests That Leverage Multi-parametric, Single-cell Biophysical Markers And Machine Learning

Chat with this insight

Recent Analyst Ratings for $BRKR

$BRKR Press Releases

Fastest customizable press release news feed in the world

Bruker Announces Quarterly Dividend

Bruker Corporation to Present at Upcoming Investor Conferences

Dragonfly Energy and Bruker Partner to Accelerate Battery Technology Development

$BRKR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Bruker Corporation

Amendment: SEC Form SC 13G/A filed by Bruker Corporation

Amendment: SEC Form SC 13G/A filed by Bruker Corporation

$BRKR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT & CEO Laukien Frank H bought $5,014,069 worth of shares (100,000 units at $50.14), increasing direct ownership by 0.26% to 38,439,563 units (SEC Form 4)

Director Rosenthal Bob exercised 12,500 shares at a strike of $23.37 and sold $295,748 worth of shares (4,684 units at $63.14), increasing direct ownership by 34% to 30,963 units (SEC Form 4)

PRESIDENT CALID Srega Juergen was granted 16,936 shares, increasing direct ownership by 12% to 157,727 units (SEC Form 4)

$BRKR Leadership Updates

Live Leadership Updates

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

Bruker Announces Agreement to Acquire Chemspeed

$BRKR Financials

Live finance-specific insights

$BRKR Market Insights

Live Market Insights

Bruker Announces Quarterly Dividend

Bruker Announces Date and Time of Third Quarter 2024 Earnings Release and Webcast

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery

Bruker Posted Bond In Order To Suspend Injunction That Had Been Impacting Sales Of CosMx Spatial Molecular Imager Products By Its NanoString Business In Germany

Citigroup Maintains Buy on Bruker, Lowers Price Target to $80

Goldman Sachs Maintains Sell on Bruker, Lowers Price Target to $60

$BRKR SEC Filings

Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Bruker Corporation

Bruker Corporation filed SEC Form 8-K: Leadership Update

$BRKR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Barclays initiated coverage on Bruker with a new price target

Bruker downgraded by Wolfe Research

Wells Fargo initiated coverage on Bruker with a new price target

$BRKR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT & CEO Laukien Frank H bought $5,014,069 worth of shares (100,000 units at $50.14), increasing direct ownership by 0.26% to 38,439,563 units (SEC Form 4)

Recent Analyst Ratings for
$BRKR

$BRKR
Press Releases

$BRKR
Large Ownership Changes

$BRKR
Insider Trading

$BRKR
Leadership Updates

$BRKR
Financials

$BRKR
Market Insights

$BRKR
SEC Filings

$BRKR
Analyst Ratings

$BRKR
Insider Purchases